UCB : Covid pushes back approval review of bimekizumab
>Approval of bimekizumab postponed - We learned at the weekend that the FDA was postponing approval of bimekizumab in the treatment of moderate to severe psoriasis.The FDA has indicated that it was unable to conduct the inspections of European facilities where bimekizumab is produced, which is a mandatory prerequisite to approval on the US market. The explanation given is to blame the travel restrictions associated with Covid. According to the company, the FDA ...UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.